Patient characteristics | Total | Dysfunctional agr (N = 10) | Functional agr (N = 159) | P-value |
---|---|---|---|---|
Male sex, N (%) | 162 (60.22) | 5 (50.00) | 157 (60.62) | 0.5253 |
Age (months), median (IQRa) | 11.9 (1.27–55.14) | 33.27 (13.15–108.38) | 11.33 (1.17–54.90) | 0.0797 |
Age distribution | Â | Â | Â | 0.1581 |
  ≤ 28 days | 59 (21.93) | 0 | 59 (22.78) |  |
 29 days–3 years | 137 (50.93) | 7 (70.00) | 130 (50.19) |  |
 4–6 years | 28 (10.41) | 0 | 28 (10.81) |  |
 7–15 years | 45 (16.73) | 3 (30.00) | 42 (16.22) |  |
Origin, N (%) | Â | Â | Â | 0.0102 |
 CA | 135 (50.19) | 1 (10.00) | 134 (51.74) |  |
 HA | 134 (49.81) | 9 (90.00) | 125 (48.26) |  |
Disease | Â | Â | Â | 0.2900 |
 Invasive infectionb, N (%) | 80 (29.74) | 1 (10.00) | 9 (90.00) |  |
 Non-invasive infectionc, N(%) | 189 (70.26) | 79 (30.50) | 180 (69.50) |  |
Vancomycin treatment, N (%) | 66 (24.54) | 2 (20.00) | 64 (24.71) | 1.0000 |
Linezolid treatment, N (%) | 45 (16.73) | 2 (20.00) | 43 (16.60) | 0.6758 |
Hospitalization-Median (IQR) | 15 (10–24) | 21 (10.25–30.25) | 14 (10–23) | 0.4000 |